3.1 The 2023 DME failure (GLEAM/GLIMMER)

Kodiak’s original ambition was broad: use tarcocimab as a long-acting anti-VEGF across wet AMD, DME, RVO and DR. The Phase 3 GLEAM and GLIMMER trials in DME were meant to be a cornerstone of this plan.

Instead, the studies failed to meet their primary BCVA endpoints versus aflibercept, and a higher rate of cataract surgery showed up in the tarcocimab arms. The company publicly stated that it would discontinue the DME development program, and the market priced that as an almost total loss of value for the asset.

3.2 The positive pieces: BEACON (RVO) and DAYLIGHT (wAMD)

Parallel to the DME flop, tarcocimab actually looked strong in other indications:

• BEACON (RVO) delivered clinically meaningful vision gains and anatomical improvements with robust durability.
• DAYLIGHT (wAMD) used monthly dosing and showed non-inferior BCVA outcomes vs aflibercept, essentially demonstrating that the molecule itself could perform when pushed aggressively.

These studies suggested the drug was not “broken” per se – the problem looked more like indication-specific safety and dosing in DME.

3.3 GLOW1 (DR) – the key proof of concept

GLOW1 Phase 3 in non-proliferative DR took a different angle:

• Patients received tarcocimab 5 mg given every six months (after loading) vs sham injections.
• The primary endpoint was the proportion achieving a ≥2-step DRSS improvement at week 48.
• The result: 41.1% of tarcocimab patients responded vs 1.4% on sham – with all active patients on fixed 6-month dosing.

Clinically, this demonstrated two important things:

• A meaningful disease-modifying effect on DR, reducing the risk of progression to proliferative disease and vision-threatening complications.
• The feasibility of a “twice-yearly” injection schedule for every patient, not just a subset that can be stretched.

From an investor perspective, GLOW1 was the bridge that allowed Kodiak to rebuild a pipeline around DR and wAMD, despite the DME setback.

4.1 GLOW2 (Phase 3, DR) – the imminent catalyst

Design: GLOW2 is a randomized, double-masked, multi-center Phase 3 trial in DR, evaluating tarcocimab 5 mg vs sham. All patients on active treatment receive fixed dosing with a 48-week treatment period. The primary endpoint is again a ≥2-step improvement on the DRSS at week 48.

Status & timelines:

• Enrollment completed with >250 patients, exceeding the original target.
• Because the study is 48 weeks long, Kodiak has stated that all primary endpoint visits should be completed by the end of January 2026.
• The company guides for topline data in Q1 2026, i.e. sometime after patients finish their week-48 visits and data cleaning is done.

If GLOW2 confirms GLOW1 with a clean safety profile, Kodiak will have the kind of back-to-back Phase 3 data in DR that can support a regulatory submission and a serious commercial narrative around twice-yearly dosing. If the signal is weaker or inconsistent, the “reboot” thesis around tarcocimab becomes much harder to defend.

4.2 DAYBREAK (Phase 3, wAMD) – the next chapter

DAYBREAK is a three-arm Phase 3 study in neovascular (wet) AMD comparing:

• tarcocimab tedromer at extended dosing intervals,
• tabirafusp tedromer (another ABC-based molecule),
• vs aflibercept as an active control.

The trial is active but not recruiting, with a start date in August 2024 and last updates in late 2025. Kodiak has communicated that topline DAYBREAK data are also expected in 2026, making wAMD a second, staggered catalyst after GLOW2.

Strategically, success in DR alone may already justify a meaningful valuation, but positive DAYBREAK results would push tarcocimab deeper into the more crowded wet AMD arena and expand peak-sales scenarios.

Over the last 18–24 months KOD has gone through a full sentiment cycle:

• 2023: “failed story”, traded below cash after the DME flop.
• 2024: quiet accumulation and re-rating as GLOW1 data in DR gained visibility.
• 2025: explosive move after GLOW1 and business updates, then the December equity raise with strong anchor support.

Current features of the tape:

• High institutional ownership with Baker Bros. as the anchor, plus other specialist biotech funds.
• Elevated short interest (>8% of float by some data providers, >16% by others depending on methodology) and several days to cover – enough to amplify moves.
• KOD appears frequently in discussions of “high-beta biotech catalyst baskets” where traders use it as a pure directional bet into GLOW2.

The net effect: this is not an under-owned, overlooked story. It is a crowded, high-conviction name for both bulls and bears – which means outcomes around GLOW2 can easily overshoot in either direction before finding a new equilibrium.

7.1 High-level scenarios (conceptual, not predictive)

• Scenario A – Clean win: GLOW2 replicates or improves on GLOW1, safety is clean, and Kodiak signals a clear path to filing in DR. The market starts to treat tarcocimab as a credible twice-yearly DR therapy with real commercial potential, and attention shifts to DAYBREAK as the next value-adder.
• Scenario B – Mixed but salvageable: primary endpoint technically met, but effect size is lower than hoped or safety raises new questions. The market spends months debating how “good is good enough” versus existing and emerging options.
• Scenario C – Miss or problematic safety: GLOW2 fails on efficacy or shows a safety pattern that undermines confidence. In that case, most of the equity value being built around DR would unwind, and the company would be forced to re-evaluate both strategy and financing.

None of these scenarios is a recommendation: they simply illustrate how binary the GLOW2 readout is for KOD, given its pre-revenue status and concentrated pipeline.

7.2 Key risks to keep in mind

• Single-asset dependency: tarcocimab dominates the investment case.
• Competition: DR and wAMD are crowded spaces with potent incumbents (Eylea, Vabysmo, others) and multiple long-acting and gene therapy approaches in development.
• Financing risk: even with the December raise, Kodiak is not funded to profitability; further capital (or partnerships) will likely be needed if the program advances.
• Volatility & positioning: high short interest, high institutional concentration and strong recent performance all increase the odds of overshooting on good or bad news.

• Watch for any January corporate updates (healthcare conferences, JPM, etc.) where management may reiterate timelines and give colour on data cleaning and regulatory discussions.
• Track volume and positioning as we approach February–March; sharp run-ups or drawdowns without news can be signals of option activity or de-risking.
• When topline lands, pay attention not only to “headline success/failure” but also to: DRSS responder rates vs GLOW1, serious ocular AEs, cataract or inflammation signals, and any comments on how regulators view the totality of data.
• Keep DAYBREAK and other pipeline elements on the radar; even a strong GLOW2 does not make DAYBREAK risk disappear, and vice versa.